Last update 08 May 2025

CD33 x DNA

Basic Info

Related Targets
CD33DNA

Related

2
Drugs associated with CD33 x DNA
Gemtuzumab Ozogamicin
Target
CD33 x DNA
Mechanism
CD33 inhibitors [+1]
Active Org.
Pfizer Europe MA EEIG [+5]
Originator Org.
Pfizer Inc.Pfizer Inc.
Active Indication
CD33-positive Acute Myeloid Leukemia [+5]
Inactive Indication
acute leukemia [+4]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
United States
First Approval Date17 May 2000
Vadastuximab talirine
Target
CD33 x DNA
Mechanism
CD33 inhibitors [+1]
Active Org.-
Originator Org.
Seagen, Inc.Seagen, Inc.
Active Indication-
Inactive Indication
Acute Myeloid Leukemia [+5]
Drug Highest PhaseDiscontinued
First Approval Ctry. / Loc.-
First Approval Date20 Jan 1800
115
Clinical Trials associated with CD33 x DNA
NCT05662904
/ Not yet recruitingPhase 1IIT
Genetic Ablation of CD33 in Hematopoietic Stem Cells to Broaden the Therapeutic Index of CD33-directed Immunotherapy in Patients with Acute Myeloid Leukemia (AML)
NCT06448013
/ RecruitingPhase 1
A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia
100 Clinical Results associated with CD33 x DNA
Login to view more data
100 Translational Medicine associated with CD33 x DNA
Login to view more data
0 Patents (Medical) associated with CD33 x DNA
Login to view more data

Analysis

Perform a panoramic analysis of this field.
login
or
view full example data
Perform a panoramic analysis of this field.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free